Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.61 |
| ▸ | ELOC | Q15369 | 1/20 | 0.61 |
| ▸ | ELOB | Q15370 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | GRK2 | P25098 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.53 |
| ▸ | AOC2 | O75106 | 3/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109402 | 0.80 | AOC2 (0.56) | VHLELOCELOBAOC2LOXL2 | |
| Hydrochloric Acid SCHEMBL21382427 | 0.80 | VHL (0.55) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL20319186 | 0.80 | VHL (0.67) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL13461836 | 0.76 | VHL (0.61) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL16242550 | 0.76 | VHL (0.61) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL1260586 | 0.76 | VHL (0.61) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL4049582 | 0.76 | VHL (1.00) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL5603565 | 0.76 | VHL (0.61) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL4240069 | 0.76 | VHL (0.61) | VHLELOCELOBPOLBNSD2 | |
| SCHEMBL28801815 | 0.74 | VHL (0.59) | VHLELOCELOBPOLBNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016087603-A1 | PROCESS FOR PREPARING A MODIFIED NATURAL RUBBER BY MEANS OF A MODIFIER | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) | 2016-06-09 | — | — | WO | claimed |
| US-12391781-B2 | Black particles, black coating material, coating film, and black matrix for color filters | SEKISUI CHEMICAL CO., LTD. (JP) | 2025-08-19 | — | — | US | disclosed |
| EP-4063426-B1 | BLACK PARTICLES, BLACK COATING MATERIAL, COATING FILM, AND BLACK MATRIX FOR COLOR FILTERS | SEKISUI CHEMICAL CO LTD (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-11-21 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| CN-114502677-B | Black particles, black paint, coating film, and black matrix for color filter | 积水化学工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| US-20220411553-A1 | BLACK PARTICLES, BLACK COATING MATERIAL, COATING FILM, AND BLACK MATRIX FOR COLOR FILTERS | SEKISUI CHEMICAL CO., LTD. (JP) | 2022-12-29 | — | — | US | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-1308414-C | Pyrromethene metal complex and light emitting device composition and light emitting devices using the same | TORAY INDUSTRIES (JP) | 2007-04-04 | — | — | CN | disclosed |
| CN-1863777-A | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LAB (US) | 2006-11-15 | — | — | CN | disclosed |
| CN-1257158-C | N-aryl substituted-1H-pyrrole derivative possessing cardiovascular activity | UNIV CHINA PHARMA (CN) | 2006-05-24 | — | — | CN | disclosed |
| CN-1690162-A | Pyrromethene metal complex and light emitting device composition and light emitting devices using the same | TORAY INDUSTRIES (JP) | 2005-11-02 | — | — | CN | disclosed |
| CN-1612663-A | Light-emitting element, light-emitting device using the light-emitting element, and electric appliance using the light-emitting device | SEMICONDUCTOR ENERGY LAB (JP) | 2005-05-04 | — | — | CN | disclosed |
| CN-1592522-A | Electroluminescent element and light-emitting device including the same | SEMICONDUCTOR ENERGY LAB (JP) | 2005-03-09 | — | — | CN | disclosed |
| CN-1544418-A | N-aryl substituted-1H-pyrrole derivative possessing cardiovascular activity | 中国药科大学 | 2004-11-10 | — | — | CN | disclosed |
| CN-1390841-A | Methylene pyrrole metal complex, material for luminating element containing it and luminating element | TORAY INDUSTRIES (JP) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | VHL 4220/4885ELOC 1168/4885ELOB 3060/4885 |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK3, CDK1, CDK2 | VHL 1209/4885ELOC 2130/4885ELOB 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.